Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention side effects of the drugs.

RAs, and DPP-4is may offer benefits for patients with COPD, but clinical evidence comparing their effectiveness in reducing ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Researchers at Columbia University Irving Medical Center have identified the specific neurons in mice brains that tell them ...